Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 342

1.

Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians.

Suriapranata IM, Tjong WY, Wang T, Utama A, Raharjo SB, Yuniadi Y, Tai SS.

BMC Med Genet. 2011 Jun 6;12:80. doi: 10.1186/1471-2350-12-80.

2.

CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.

Cen HJ, Zeng WT, Leng XY, Huang M, Chen X, Li JL, Huang ZY, Bi HC, Wang XD, He YL, He F, Zhou RN, Zheng QS, Zhao LZ.

Br J Clin Pharmacol. 2010 Aug;70(2):234-40. doi: 10.1111/j.1365-2125.2010.03698.x.

3.

Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.

Rusdiana T, Araki T, Nakamura T, Subarnas A, Yamamoto K.

Eur J Clin Pharmacol. 2013 Mar;69(3):395-405. doi: 10.1007/s00228-012-1356-9. Epub 2012 Aug 2.

PMID:
22855348
4.

Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.

Krishna Kumar D, Shewade DG, Loriot MA, Beaune P, Balachander J, Sai Chandran BV, Adithan C.

Eur J Clin Pharmacol. 2014 Jan;70(1):47-56. doi: 10.1007/s00228-013-1581-x. Epub 2013 Sep 10.

PMID:
24019055
5.

A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation.

Wei M, Ye F, Xie D, Zhu Y, Zhu J, Tao Y, Yu F.

Thromb Haemost. 2012 Jun;107(6):1083-91. doi: 10.1160/TH11-12-0848. Epub 2012 Apr 26.

PMID:
22534826
6.

Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.

Borgiani P, Ciccacci C, Forte V, Romano S, Federici G, Novelli G.

Pharmacogenomics. 2007 Nov;8(11):1545-50.

PMID:
18034619
7.

Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients.

Choi JR, Kim JO, Kang DR, Yoon SA, Shin JY, Zhang X, Roh MO, Hong HJ, Wang YP, Jo KH, Lee KS, Yun HJ, Oh YS, Yoo KD, Jeon HG, Lee YS, Kang TS, Park HJ, Chung MW, Kang JH.

J Hum Genet. 2011 Apr;56(4):290-5. doi: 10.1038/jhg.2011.4. Epub 2011 Feb 17.

PMID:
21326313
8.

Genetic determinants of warfarin dosing in the Han-Chinese population.

Lee MT, Chen CH, Chou CH, Lu LS, Chuang HP, Chen YT, Saleem AN, Wen MS, Chen JJ, Wu JY, Chen YT.

Pharmacogenomics. 2009 Dec;10(12):1905-13. doi: 10.2217/pgs.09.106.

PMID:
19958090
9.

Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.

Carlquist JF, Horne BD, Muhlestein JB, Lappé DL, Whiting BM, Kolek MJ, Clarke JL, James BC, Anderson JL.

J Thromb Thrombolysis. 2006 Dec;22(3):191-7.

PMID:
17111199
10.

Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.

Liang R, Li L, Li C, Gao Y, Liu W, Hu D, Sun Y.

J Thromb Thrombolysis. 2012 Jul;34(1):120-5. doi: 10.1007/s11239-012-0725-7.

PMID:
22528326
11.

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

Yuan HY, Chen JJ, Lee MT, Wung JC, Chen YF, Charng MJ, Lu MJ, Hung CR, Wei CY, Chen CH, Wu JY, Chen YT.

Hum Mol Genet. 2005 Jul 1;14(13):1745-51. Epub 2005 May 11.

PMID:
15888487
12.

A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.

Tham LS, Goh BC, Nafziger A, Guo JY, Wang LZ, Soong R, Lee SC.

Clin Pharmacol Ther. 2006 Oct;80(4):346-55.

PMID:
17015052
13.

Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations.

Gan GG, Phipps ME, Lee MM, Lu LS, Subramaniam RY, Bee PC, Chang SH.

Ann Hematol. 2011 Jun;90(6):635-41. doi: 10.1007/s00277-010-1119-6. Epub 2010 Nov 26.

PMID:
21110192
14.

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.

Ozer N, Cam N, Tangurek B, Ozer S, Uyarel H, Oz D, Guney MR, Ciloglu F.

Heart Vessels. 2010 Mar;25(2):155-62. doi: 10.1007/s00380-009-1177-7. Epub 2010 Mar 26.

PMID:
20339978
15.

[Impact of five genetic polymorphisms on inter-individual variation in warfarin maintenance dose].

Huang SW, Xiang DK, Wu HL, Chen BL, An BQ, Li GF.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2011 Dec;28(6):661-5. doi: 10.3760/cma.j.issn.1003-9406.2011.06.014. Chinese.

PMID:
22161100
16.

Effect of VKORC1, CYP2C9, CFP4F2, and GGCX Gene Polymorphisms on Warfarin Dose in Japanese Pediatric Patients.

Wakamiya T, Hokosaki T, Tsujimoto S, Kadota K, Nakano Y, Watanabe S, Iwamoto M, Yanagimachi M, Ito S.

Mol Diagn Ther. 2016 Aug;20(4):393-400. doi: 10.1007/s40291-016-0212-5. Erratum in: Mol Diagn Ther. 2016 Oct;20(5):501.

PMID:
27262824
17.

Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.

Özer M, Demirci Y, Hizel C, Sarikaya S, Karalti İ, Kaspar Ç, Alpan S, Genç E.

Basic Clin Pharmacol Toxicol. 2013 Mar;112(3):209-14. doi: 10.1111/bcpt.12024. Epub 2012 Dec 6.

18.

Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.

Ekladious SM, Issac MS, El-Atty Sharaf SA, Abou-Youssef HS.

Mol Diagn Ther. 2013 Dec;17(6):381-90. doi: 10.1007/s40291-013-0046-3.

PMID:
23839801
19.

Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate.

Palacio L, Falla D, Tobon I, Mejia F, Lewis JE, Martinez AF, Arcos-Burgos M, Camargo M.

Clin Appl Thromb Hemost. 2010 Feb;16(1):83-90. doi: 10.1177/1076029608330472. Epub 2009 Jun 29.

PMID:
19567378
20.

Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism.

Zhang W, Zhang WJ, Zhu J, Kong FC, Li YY, Wang HY, Yang YH, Wang C.

Pharmacogenomics. 2012 Feb;13(3):309-21. doi: 10.2217/pgs.11.147. Epub 2012 Jan 17.

PMID:
22248286

Supplemental Content

Support Center